GlassScriptPhysician profile
Corwin Jawayne Rankin
NPI 1295939916
$620.46
in general payments reported to CMS, 2019-2025
11 companies · $133 in 2025
The $133 reported for 2025 was more than what a typical Hospitalist provider received nationally (typical 2025 total: $85.87).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $15.41 · 2023: $186 · 2024: $285 · 2025: $133.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $605.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $605.05 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $158.83 | 2023-2025 | Dificid, Zerbaxa, Recarbrio |
| Abbvie INC. | $120.45 | 2023-2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $62.92 | 2023-2024 | Jardiance |
| Novartis Pharmaceuticals Corporation | $54.77 | 2024 | |
| Electromed, INC. | $51.23 | 2023-2024 | Smartvest |
| Verona Pharma, INC. | $47.09 | 2025 | Ohtuvayre |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $37.43 | 2023-2024 | Lifevest |
| Inari Medical, INC. | $33.24 | 2023 | Flowtriever Catheter, S, Ct Thrombectomy System Kit |
| Kestra Medical Technology Services, INC. | $22.39 | 2025 | Assure Wcd |
| Astrazeneca Pharmaceuticals LP | $16.70 | 2023 | Fasenra |
| Masimo Corporation | $15.41 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Corwin Rankin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.